The Dietary Constituent Falcarindiol Promotes Cholesterol Efflux from THP-1 Macrophages by Increasing ABCA1 Gene Transcription and Protein Stability

Limei Wang1,2, Veronika Palme1, Nicole Schilcher1, Angela Ladurner1, Elke H. Heiss1, Herbert Stangl3, Rudolf Bauer4, Verena M. Dirsch1 and Atanas G. Atanasov1,5*

1 Department of Pharmacognosy, University of Vienna, Vienna, Austria, 2 Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China, 3 Center for Pathobiology and Genetics, Institute of Medical Chemistry, Medical University of Vienna, Vienna, Austria, 4 Department of Pharmacognosy, Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Graz, Austria, 5 Department of Molecular Biology, Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, Lesznowola, Poland

We report increased cholesterol efflux from macrophages in the presence of falcarindiol, an important dietary constituent present in commonly used vegetables and medicinal plants. Falcarindiol (3–20 µM) increased cholesterol efflux from THP-1-derived macrophages. Western blot analysis showed an increased protein level of ABCA1 upon falcarindiol exposure. Quantitative real-time PCR revealed that also ABCA1 mRNA level rise with falcarindiol (10 µM) treatment. The effect of falcarindiol on ABCA1 protein as well as mRNA level were counteracted by co-treatment with BADGE, an antagonist of PPARγ. Furthermore, falcarindiol significantly inhibited ABCA1 protein degradation in the presence of cycloheximide. This post-translational regulation of ABCA1 by falcarindiol occurs most likely by inhibition of lysosomal cathepsins, resulting in decreased proteolysis and extended protein half-life of ABCA1. Taken together, falcarindiol increases ABCA1 protein level by two complementary mechanisms, i.e., promoting ABCA1 gene expression and inhibiting ABCA1 protein degradation, which lead to enhanced cholesterol efflux.

Keywords: falcarindiol, cholesterol efflux, ABCA1, protein degradation, PPARγ

INTRODUCTION

Cardiovascular disease (CVD) associated with atherosclerosis is a leading cause of mortality in the world. Cholesterol metabolism has been considered as a major player in the pathogenesis of CVD. Excessive cholesterol deposition resulting in plaques is a critical cause of atherosclerosis. Reverse cholesterol transport (RTC) is a complex multi-step process overall resulting in the relocation of cholesterol from peripheral tissues to the liver for excretion into the bile and ultimately the feces. Cholesterol efflux, the initial step of RTC, is known to enhance the export of excessive cholesterol from peripheral tissues, in particular macrophages, and thereby to inhibit the accumulation of cholesterol in the wall of arteries (Fielding and Fielding, 1995). There is strong evidence that the cholesterol efflux capacity is inversely associated with the
The dietary constituent falcarindiol promotes macrophage cholesterol efflux by increasing ABCA1 transporter gene transcription (via PPARγ activation) and protein stability (via inhibition of lysosomal proteolysis).

incidence of CVD (Rohatgi et al., 2014). Therefore, the enhancement of cholesterol efflux from macrophages might prevent CVD, making it a potential strategy for pharmacological interventions. Key determinant of cholesterol efflux is the expression level and activity of transmembrane transporter proteins such as the ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) and the scavenger receptor class B member 1 (SR-B1) (Duffy and Rader, 2006). Among them, ABCA1 is the predominant one and it contributes to most of the cholesterol transport in macrophages (Rosenson et al., 2012; Du et al., 2015). ABCA1 mediates mostly transfer of cholesterol to lipid–poor apolipoprotein A1 (apo A1), but it can also mediate cholesterol transport using high density lipoproteins (HDL) as an acceptor (Du et al., 2015). Modulation of the ABCA1 protein level is considered an important regulator for cholesterol efflux. In general, the level of ABCA1 protein is determined by de novo synthesis and protein degradation. Several nuclear receptors are implicated in the regulation of ABCA1 gene transcription. Thus, the activation of the ligand-dependent nuclear receptors peroxisome proliferator-activated receptor gamma (PPARγ) and subsequently the liver X receptor (LXR), can lead to increased ABCA1 gene transcription (Chawla et al., 2001; Chinetti et al., 2001; Ozasa et al., 2011). The ABCA1 protein half-life is largely regulated via the proteolytic activity of calpain-, lysosome-, and ubiquitin-degradation pathways (Wang et al., 2003; Mizuno et al., 2011; Liu and Tang, 2012; Yokoyama et al., 2012). Cathepsins represent key lysosomal proteases (Turk et al., 2012) and diverse cathepsin isoforms (e.g., cathepsin B, D, K, L, S) are known to be expressed in macrophages (Punturieri et al., 2000; Beers et al., 2003; Bracke et al., 2005; Vasiljeva et al., 2006).

Natural products have proven to be an excellent source of molecules with promising pharmacological activities and novel mechanisms of action (Atanasov et al., 2015). Here, we report the identification and characterization of the natural product falcarindiol (Figure 1A) as a novel enhancer of macrophage cholesterol efflux. Falcarindiol is a C(17)-polyacetylene and a typical constituent of roots and rhizomes of Apiaceae plants used worldwide, including in Europe, such as the commonly used vegetables and herbs carrot (Daucus carota L.) (Garrod et al., 1978), celery (Apium graveolens L.) (Zidorn et al., 2005), Notopterygium incisum K.C.Ting ex H.T.Chang (Zschocke et al., 1997), and Aegopodium podagraria L. (Kemp, 1978), among others. Taking the important role of PPARγ in the regulation of macrophage cholesterol efflux into consideration, we have chosen this natural product as a study subject in the context of cholesterol efflux because falcarindiol, extracted from the rhizomes and roots of Notopterygium incisum K.C.Ting ex H.T.Chang, was recently identified as a partial PPARγ agonist in HEK-293 cells transfected with a PPARγ-responsive luciferase reporter (Atanasov et al., 2013).

MATERIALS AND METHODS

Chemical Reagents

Roswell Park Memorial Institute 1640 (RPMI-1640) medium was obtained from Lonza (Basel, Switzerland). Fetal bovine serum (FBS) was purchased from Gibco via Invitrogen (Lofer, Austria). [3H]-Cholesterol was bought from Perkin Elmer Life Sciences (Vienna, Austria) and pioglitazone was from Molekula (Munich, Germany). Albumin faction V, fatty acid free BSA was obtained from Carl Roth (Graz, Austria). Bisphenol A diglycidyl ether (BADGE), resazurin sodium salt, water soluble unesterified cholesterol, apolipoprotein (apo) A1, phorbol 12-myristate 13-acetate (PMA), lactacystin, calpeptin, chloroquine, and cycloheximide were provided by Sigma-Aldrich (Vienna, Austria). Falcarindiol was isolated from the roots and rhizomes of the traditional Chinese herbal drug Radix Notopterygii, with a purity over 95% as determined by High Performance Liquid Chromatography (HPLC) (Zschocke et al., 1997; Liu et al., 2014). Cathepsin B, L, D, and K Activity Fluorometric kits were
purchased from BioVision via THP Medical Products GmbH (Vienna, Austria). Cathepsin S activity assay kit (fluorometric) was bought from Abcam (Cambridge, UK). Antibodies were obtained from the following companies: ABCA1, ABCG1, SR-B1 from Novus Biologicals via THP Medical Products GmbH (Vienna, Austria), anti-actin antibody from MP Biologicals (Illkirch, France), horseradish peroxidase-conjugated goat anti-rabbit secondary antibody from Upstate (Millipore, Vienna, Austria).

**Cell Culture**

Human monocytic THP-1 cells were acquired from ATCC® and grown in suspension in RPMI-1640 medium supplemented with 2 mM glutamine, 100 U/mL benzylpenicillin, 100 mg/mL streptomycin, and 10% FBS in T175 flasks. For experiments, differentiation was induced by seeding THP-1 monocytes in 96-, 24-, or 6- well plates under treatment of 200 nM PMA for 72 h (seeding cell density of 0.2 × 10^6 cells per mL). All of the tested compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at −20°C. Control cells were always treated with an equal volume of solvent (DMSO) and its final concentrations did not exceed 0.1%.

**Cholesterol Efflux Assay**

The cholesterol efflux assay (Wang et al., 2015) was adapted from previous studies (Chawla et al., 2001; Chinetti et al., 2001). Briefly, THP-1-derived macrophages were incubated for 24 h with the compounds at the indicated concentrations [solvent vehicle (DMSO), falcarindiol (1–20 µM), the PPARγ agonist pioglitazone (10 µM) as positive control] together with [3H]-cholesterol in serum free medium supplemented with 0.1% BSA and 10 µg/mL unesterified cholesterol. On the next day, cells were washed twice with pre-warmed PBS and incubated with the same compounds [solvent vehicle (DMSO), falcarindiol (1–20 µM for apo A1-mediated cholesterol efflux, or 10 µM for human plasma-mediated cholesterol efflux), or the PPARγ agonist pioglitazone (10 µM) as positive control] with or without 10 µg/mL apo A1 or 1% human plasma dissolved in serum-free medium for 6 h. Extracellular as well as intracellular radioactivity were quantified with a scintillation counter. All values are means ± SD (n = 3) and vs. solvent vehicle control (DMSO): *p < 0.05, **p < 0.01, ***p < 0.001, n.s, not significant (ANOVA/Bonferroni).
with scintillation counting. The apo A1- as well as human plasma-mediated cholesterol efflux was calculated as follows:

\[
\text{Apo A1 mediated cholesterol efflux \%} = \frac{\left( \frac{\text{extracellular cpm}}{\text{total cpm}} \right) \text{apo A1} - \left( \frac{\text{extracellular cpm}}{\text{total cpm}} \right) \text{no apo A1}}{\left( \frac{\text{extracellular cpm}}{\text{total cpm}} \right) \text{no apo A1}} \times 100
\]

\[
\text{Human plasma mediated cholesterol efflux \%} = \frac{\left( \frac{\text{extracellular cpm}}{\text{total cpm}} \right) \text{plasma} - \left( \frac{\text{extracellular cpm}}{\text{total cpm}} \right) \text{no plasma}}{\left( \frac{\text{extracellular cpm}}{\text{total cpm}} \right) \text{no plasma}} \times 100
\]

**Resazurin Conversion Assay**
The viability of THP-1-derived macrophages was assessed by resazurin conversion. The assay was performed as previously described (Wang et al., 2015) by quantification of the conversion of the low fluorescent resazurin to high fluorescent resorufin.

**Gel Electrophoresis and Immunoblot Analysis**
THP-1 cells were seeded in 6-well plates and differentiated into macrophages with 200 nM PMA for 72 h. The macrophages were treated with the indicated compounds at the corresponding time points, as described in detail in each figure legend. Cellular proteins were extracted using NP40 buffer (150 mM NaCl; 50 mM HEPES (pH 7.4); 1% NP40; 1% protease inhibitor Complete™ (Roche); 1% phenylmethylsulfonyl fluoride (PMSF); 0.5% Na3VO4; 0.5% NaF) and quantified with the Bradford method. For western blot analysis, an equal amount of protein (20 µg) was separated via SDS-PAGE and transferred onto a PVDF membrane. The membrane was blocked for 1 h at room temperature with 5% non-fat milk, then incubated at 4 °C overnight with primary polyclonal antibody against ABCA1, ABCG1 or SR-B1 (1:500) or actin. The indicated protein band intensity was normalized to that of actin.

**RNA Extraction and Analysis**
THP-1 cells were seeded in 6-well plates and differentiated into macrophages with 200 nM PMA treatment for 72 h. The macrophages were treated with the indicated compounds at the indicated time points, as described in detail in the figure legends. Total cellular RNA was extracted from the treated THP-1 macrophages using peqGOLD Total RNA kits (PeqLab, Linz, Austria) according to the manufacturer’s instructions. One microgram of total RNA was used for cDNA synthesis according to the protocol of the High Capacity cDNA Reverse Transcription Kit together with RNase Inhibitor (Applied Biosystems). LightCycler® 480 SYBR Green I Master kit (Roche) was used for quantitative real-time PCR (qRT-PCR) with 40 ng cDNA from each sample for triplicate measurements. Amplification cycles were detected using the LightCycler 480 system (Roche). ABCA1 (HS_ABCA1_1_SG QuantiTect primer assay, Cat.no.: #QT00064869, QIAGEN) and 18S (Hs_RRN18S_1_SG QuantiTect Primer assay, Cat.no.: #QT00199367, QIAGEN) primers were used, and the quantification was performed with the ΔCT method.

**Determination of Cathepsin Activity**
The cathepsin activity assays were performed according to the manufacturer’s instructions. In general, THP-1-derived macrophages were cultured for 24 h with solvent control (DMSO) or falcarindiol (10 µM). After incubation, cells were washed once with cold PBS and lysed with chilled cell lysis buffer. Protein concentration was determined using the Bradford method. Hundred micrograms of protein per reaction in 50 µL of cell lysis buffer was used for the activity measurement. Fifty microliters of reaction buffer and 2 µL of the respective cathepsin substrate were added to 50 µL cell lysates. The assay plate was incubated at 37°C for 1 h protected from light. The fluorescence was quantified with Tecan Infinite 200® Pro plate reader (Vienna, Austria).

**Statistical Methods**
Statistical analysis was performed with data acquired from at least three independent experiments using GraphPad Prism software version 4.03 (GraphPad Software Inc., La Jolla, CA, USA). Figures with bar graphs represent mean ± SD. To determine statistical significance, one- or two-way analysis of variance (ANOVA) were performed and p < 0.05 was considered significant.

**RESULTS**

**Falcarindiol Promotes Cholesterol Efflux in Thp-1-Derived Macrophages**
In a previous study, we showed that falcarindiol activates PPARγ in HEK-293 cells transfected with a PPARγ-responsive luciferase reporter (Atanasov et al., 2013). Considering that PPARγ is a known regulator of cholesterol efflux (Chawla et al., 2001; Chimenti et al., 2001), we aimed to investigate whether falcarindiol can promote cholesterol efflux in THP-1-derived macrophages. Since apo A1, the nascent and lipid free form of HDL, is the most significant acceptor for cholesterol effluxed from macrophages (Du et al., 2015), we first studied cholesterol efflux mediated by apo A1. Falcarindiol enhanced apo A1-mediated cholesterol efflux in a concentration-dependent manner when applied at 1–20 µM (without effect on cell viability; Figure 1B) with a half maximal effective concentration (EC50) of 5.8 µM (Figure 1C). Moreover, 10 µM falcarindiol also significantly enhanced 1% human plasma-mediated cholesterol efflux (Figure 1D) as plasma containing HDL particles served as cholesterol acceptors in the process of cholesterol efflux. Pioglitazone, a PPARγ agonist known to upregulate cholesterol
Falcarindiol Promotes Cholesterol Efflux

Falcarindiol Enhances ABCA1 Protein Expression

The transmembrane proteins ABCA1, ABCG1, and SR-B1 are transporters mediating cholesterol efflux (Duffy and Rader, 2006). Therefore, we investigated protein expression of these three transporters upon treatment with falcarindiol in THP-1-derived macrophages. As evident in Figure 2A, ABCA1 protein level significantly increased in response to falcarindiol (10 \( \mu \)M). At the same time, there was no significant upregulation of ABCG1 (Figure 2B) or the bi-directional transporter SR-B1 (Figure 2C; Stangl et al., 1999). Next, we investigated whether increased ABCA1 protein level is associated with an increase in ABCA1 mRNA level. ABCA1 mRNA level indeed significantly increased upon falcarindiol treatment (Figure 3B, left).

In macrophages, enhanced ABCA1 mRNA level might result from PPAR\( \gamma \) and subsequent LXR activation (Chawla et al., 2001; Chinetti et al., 2001). We, therefore, asked whether the increased ABCA1 mRNA level induced by falcarindiol might be due to PPAR\( \gamma \)-activation. To check this possibility, we used the PPAR\( \gamma \) antagonist, BADGE (50 \( \mu \)M), to block the activity of PPAR\( \gamma \) in THP-1-derived macrophages (Hinz et al., 2003). Indeed, BADGE blocked the falcarindiol-mediated increase of ABCA1 protein as well as mRNA level (Figures 3A,B).

Falcarindiol Inhibits ABCA1 Protein Degradation

Interestingly, the ABCA1 mRNA up-regulation by falcarindiol was significantly lower than the mRNA induction caused by the PPAR\( \gamma \) agonist pioglitazone (Figure 3B, on the left), while the induction of ABCA1 protein level by falcarindiol and pioglitazone was equally potent (Figure 3A, on the left). This inconsistency indicated that an additional effect of falcarindiol might exist, which could enhance ABCA1 protein level besides the increase of ABCA1 mRNA level. To explore this possibility, we measured the rate of ABCA1 protein degradation in the presence and absence of falcarindiol. THP-1-derived macrophages were incubated with falcarindiol or solvent vehicle (DMSO) for 24 h and were then further treated with cycloheximide (140 \( \mu \)M) to block de novo protein synthesis (Arakawa et al., 2009). As evident in Figure 4, ABCA1 protein degradation was significantly inhibited in the presence of falcarindiol showing that the compound interferes with the ABCA1 protein turnover rate.

Falcarindiol Inhibits Lysosomal Cathepsin-Dependent ABCA1 Degradation

To further explore how falcarindiol inhibits ABCA1 protein degradation, we first investigated, which protein degradation pathway could be affected by falcarindiol in THP-1-derived macrophages. As presented in Figure 5A, the application of lactacystin, an ubiquitin proteasome inhibitor, failed to affect ABCA1 protein level in our experimental setting. However, the application of calpeptin (a calpain inhibitor) and chloroquine (a lysosome inhibitor) (Figures 5B,C) increased ABCA1 protein level, similarly to falcarindiol. Falcarindiol had an additive effect on ABCA1 protein level upon co-treatment with calpeptin, indicating that its mechanism of action is likely different from the calpain inhibitor calpeptin. However, there was no difference observed with or without chloroquine in the presence of falcarindiol, suggesting that falcarindiol might interfere with protein degradation in the lysosome, mimicking the effect of chloroquine (Figure 5C).

The lysosomal degradation pathway is a well-known regulator of ABCA1 protein turnover (Neufeld et al., 2001; Santamarina-Fojo et al., 2001; Mizuno et al., 2011) and cathepsins are well established proteases mediating the lysosomal proteolysis in general (Turk et al., 2012; Appelqvist et al., 2013). Therefore,
we investigated whether the proteolytic activity of lysosomal cathepsins is affected by falcarindiol. Figures 6A–E shows that among the tested cathepsins (B, D, K, L, S) the activity of cathepsin B, S, and K were significantly suppressed by 35, 14, and 8%, respectively. Overall, these data indicate that falcarindiol leads to the suppression of ABCA1 degradation and inhibits lysosomal cathepsins.

**DISCUSSION**

In this study, we describe for the first time that falcarindiol, a typical constituent of Apiaceae vegetables, stimulates cholesterol efflux by promoting ABCA1 gene expression in THP-1-derived macrophages. In addition, we show that falcarindiol increases ABCA1 protein stability and inhibits the proteolytic activity of lysosomal cathepsins.

Macrophage cholesterol efflux is a process counteracting the transformation of macrophages into pro-atherogenic foam cells. Thus, the study of this process and molecules that can regulate it is of significance for potential approaches to combat CVD (Rosenson et al., 2012; Du et al., 2015). ABCA1 is the most important membrane transporter for cholesterol efflux from macrophages (Du et al., 2015). Treatment of THP-1-derived macrophages with falcarindiol increased ABCA1 protein expression (Figure 2). In contrast, the expression level of the other two cholesterol transmembrane transporters, SR-B1 and ABCG1, remained unchanged. In THP-1 macrophages, SR-B1 was shown to be co-expressed with caveolin-1 and to enhance selectively cholesterol ester uptake rather than cholesterol efflux (Matveev et al., 1999). Interestingly, both ABCA1 and ABCG1 proteins seem to be tightly regulated by PPARγ as shown in studies using full agonists of PPARγ (Chawla et al., 2001; Ozasa et al., 2011). Falcarindiol, in contrast, works as a partial PPARγ agonist in HEK-293 cells (Atanasov et al., 2013). Thus, the fact that the abundance of ABCG1 protein did not significantly increase in response to falcarindiol might be explained by the partial agonism of the compound. The contribution of PPARγ to falcarindiol-induced ABCA1 protein expression was demonstrated by co-treatment experiment with BADGE, a PPARγ antagonist (Figure 3). Numerous reports
suggest a synergistic effect between ABCA1 and ABCG1 in the context of cholesterol efflux (Gelissen et al., 2006; Hsieh et al., 2014). Although they exhibited a similar degradation rate in CHO cells, ABCG1 degradation seems to work by different degradation mechanisms than that of ABCA1. In addition, there are differences in the protein stability of two ABCG1 isoforms (Gelissen et al., 2010).

We also demonstrate that falcarindiol inhibits protein degradation of ABCA1 in the presence of cycloheximide, a de novo protein synthesis inhibitor (Figure 4). Several proteolytic
pathways have been described to mediate ABCA1 degradation in different cell types, particularly the calpain-, lysosome-, and proteasome-mediated pathways (Wang et al., 2003; Mizuno et al., 2011; Liu and Tang, 2012; Yokoyama et al., 2012). Applying specific inhibitors of these three proteolytic pathways, we found that falcarindiol mimics the effect of lysosomal proteolysis inhibitor chloroquine on ABCA1 levels (Figure 5).

Cathepsins are well-established lysosomal proteases (Turk et al., 2012). A variety of cathepsins (e.g., cathepsin B, D, K, L, S) are known to be expressed and to serve important regulatory functions in macrophages (Punturieri et al., 2000; Beers et al., 2003; Bracke et al., 2005; Vasiljeva et al., 2006). Measuring the activity of lysosomal cathepsins known to be expressed in macrophages revealed that falcarindiol simultaneously suppresses the activity of cathepsin B, S, and K. Among these three cathepsins, cathepsin S and K were proposed to reduce cholesterol efflux from macrophages (Lindstedt et al., 2003; Lutgens et al., 2007) and knockout of cathepsin S or K genes was shown to lead to decreased atherosclerosis in mice (Sukhova et al., 2003; Lutgens et al., 2006). Cathepsin B was also found to be highly expressed and active in murine atherosclerotic lesions (Chen et al., 2002; Lutgens et al., 2007). The potential of cathepsin B, S, and K to influence ABCA1 protein level regulation further supports the concept for their implication in atherosclerosis. To the best of our knowledge, interference of falcarindiol with cathepsins or with lysosomal function was never reported before.

In summary, our results demonstrate for the first time that falcarindiol is able to increase macrophage cholesterol efflux. Falcarindiol upregulates ABCA1 protein level by promoting its PPARY-driven gene expression and by extending its protein half-life. Moreover, our findings reveal the inhibition of lysosomal proteases as a new possible mechanism of action of this important dietary constituent. These data advance our knowledge for the molecular mechanisms, by which small molecules regulate macrophage cholesterol efflux, and might have implication for the development of novel therapeutics or dietary supplements for the prevention or treatment of CVD.

CONCLUSION

In the present study, we demonstrated that falcarindiol enhances cholesterol efflux and increases ABCA1 protein level by two complementary mechanisms, i.e., promoting ABCA1 gene expression and inhibiting ABCA1 protein degradation.

AUTHOR CONTRIBUTIONS

IW: Performed most of the experiments, analyzed the results, and drafted the manuscript. VP and NS: Conducted the experiments concerning the expression of transporters. AA and VD: Supervised the study. All authors revised the manuscript.

ACKNOWLEDGMENTS

The authors acknowledge the financial support by the Austrian Science Fund (FWF) project (P25971-B23), the Vienna Anniversary Foundation for Higher Education (Hochschuljubiläumsstiftung der Stadt Wien) project (H-297332/2014), the Polish KNOW (Leading National Research Centre) Scientific Consortium “Healthy Animal-Safe Food,” decision of Ministry of Science and Higher Education No. 05-1/KNOW2/2015, the Qingdao Applied Basic Research on Innovation Program (17-1-1-53-jch), and the Qingdao University Research Start-up Fee for Zhuoyue Talents (41117010020). The authors also would like to thank Dr. Xin Liu (Institute of Pharmaceutical Sciences, Department of Pharmacognosy, Karl-Franzens-University Graz) for the assistance in the execution of this project.

REFERENCES

Appelqvist, H., Waster, P., Kagedal, K., and Ollinger, K. (2013). The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell Biol. 5, 214–226. doi: 10.1093/jmcb/mjt022

Arakawa, R., Tsujita, M., Iwamoto, N., Ito-Ohsumi, C., Lu, R., Wu, C. A., et al. (2009). Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenicity. J. Lipid Res. 50, 2299–2305. doi: 10.1194/jlr.M900122-JLR200

Atanasov, A. G., Blunder, M., Fakhruddin, N., Liu, X., Noha, S. M., Malainer, C., et al. (2013). Polycytenes from Notopterygium incisum-new selective partial agonists of peroxisome proliferator-activated receptor-gamma. Plas ONE 8, e61755. doi: 10.1371/journal.pone.0061755

Atanasov, A. G., Waltenberger, B., Piersch-Wenzig, E. M., Linder, T., Wawrosch, C., Uhrin, P., et al. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol. Adv. 33, 1582–1614. doi: 10.1016/j.biotechadv.2015.08.001

Beers, C., Honey, K., Fink, S., Forbush, K., and Rudensky, A. (2003). Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J. Exp. Med. 197, 169–179. doi: 10.1084/jem.20020978

Bracke, K., Cataldo, D., Maes, T., Guelders, M., Noel, A., Foidart, J. M. et al. (2005). Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. Int. Arch. Allergy Immunol. 138, 169–179. doi: 10.1159/000088439

Chawla, A., Boisvert, W. A., Lee, C. H., Laffitte, B. A., Barak, Y., Joseph, S. R., et al. (2001). A PPARY gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7, 161–171. doi: 10.1016/S1097-2765(01)00164-2

Chen, J., Tung, C. H., Mahmood, U., Nitziarchristos, V., Gyurko, R., Fishman, M. C., et al. (2002). In vivo imaging of proteolytic activity in atherosclerosis. Circulation 105, 2766–2771. doi: 10.1161/01.CIR.0000017860.20619.23

Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., et al. (2001). PPARY and PPARY-g activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7, 53–58. doi: 10.1038/83348

Du, X. M., Kim, M. J., Hou, L. M., Le Goff, W., Chapman, M. J., Van Eck, M., et al. (2015). HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ. Res. 116, 1133–1142. doi: 10.1161/CIRCRESAHA.116.305485

Duffy, D., and Rader, D. J. (2006). Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113, 1140–1150. doi: 10.1161/CIRCULATIONAHA.105.593855

Fielding, C. J., and Fielding, P. E. (1995). Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36, 211–228.

Garrod, B., Lewis, B. G., and Coxon, D. T. (1978). Cis-Heptadeca-1,9-Diene-4,6-Diyne-3,8-Diol, an antifungal polyacetylene from carrot root tissue. Physiol. Plant. Pathol. 13, 241–246. doi: 10.1016/0048-4059(78)9039-5
Gelissen, I. C., Cartland, S., Brown, A. J., Sandoval, C., Kim, M., Dinnels, D. L., et al. (2010). Expression and stability of two isoforms of ABCG1 in human vascular cells. *Atherosclerosis* 208, 75–82. doi:10.1016/j.atherosclerosis.2009.06.028

Gelissen, I. C., Harris, M., Rye, K. A., Quinn, C., Brown, A. J., Kocks, M., et al. (2006). ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. *Arterioscler. Thromb. Vasc. Biol.* 26, 534–540. doi:10.1161/01.ATV.00002008.88535.e1

Hinz, B., Brune, K., and Pahl, A. (2003). 15-Deoxy-Delta1-2-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-γ-independent mechanism. *Biochem. Biophys. Res. Commun.* 302, 415–420. doi:10.1016/S0006-291X(03)00195-5

Hsieh, V., Kim, M. J., Gelissen, I. C., Brown, A. J., Sandoval, C., Hallab, J. C., et al. (2014). Cellular cholesterol regulates ubiquitination and degradation of the cellular cholesterol export proteins ABCA1 and ABCG1. *J. Biol. Chem.* 289, 7524–7536. doi:10.1074/jbc.M113.515890

Kemp, M. S. (1978). Falcarnidol - antifungal polycyclactone from Aegopodium podagraria. *Phytochemistry* 17, 1002–1002. doi:10.1016/S0031-9422(00)88669-0

Lindstedt, L., Lee, M., Oorni, K., Bromme, D., and Kovanen, P. T. (2003). Cathepsins F and S block HDL3-induced cholesterol efflux from macrophage foam cells. *Biochem. Biophys. Res. Commun.* 312, 1019–1024. doi:10.1016/j.bbrc.2003.11.020

Liu, X., Kunert, O., Blumberg, M., Fakhrudin, N., Noha, S. M., Malainer, C., et al. (2014). Polynye hybrid compounds from *Notopterygium incisum* with peroxisome proliferator-activated receptor γ agonist effects. *J. Nat. Prod.* 77, 2513–2521. doi:10.1021/np500605v

Liu, Y. H., and Tang, C. R. (2012). Regulation of ABCA1 functions by signaling pathways. *Biochim. Biophys. Acta* 1821, 522–529. doi:10.1016/j.bbapal.2011.08.015

Lutgens, E., Lutgens, S. P., Faber, B. C., Heeneman, S., Gijbels, M. M., de Winther, M. P., et al. (2006). Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. *Circulation* 113, 98–107. doi:10.1161/CIRCULATIONAHA.105.561449

Lutgens, S. P., Cleutjens, K. B., Daemen, M. J., and Heeneman, S. (2007). Cathepsin cysteine proteases in cardiovascular disease. *FASEB J.* 21, 3029–3041. doi:10.1096/fj.07-7924com

Matveev, S., van der Westhuyzen, D. R., and Smart, E. J. (1999). Co-expression of scavenger receptor-BI and caveolin-1 is associated with enhanced selective peroxisome proliferator-activated receptor gamma agonistic effects. *J. Clin. Invest.* 111, 897–906. doi:10.1172/JCI200314915

Neufeld, E. B., Remaley, A. T., Demosky, S. J., Stonik, J. A., Cooney, A. M., Comly, M., et al. (2006). Cholesterol efflux and atheroprotection advancing the concept of reverse cholesterol transport. *Circulation* 125, 1905–1919. doi:10.1161/CIRCULATIONAHA.111.066589

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Wang, Palme, Schlücher, Ladurner, Heiss, Stangl, Bauer, Dirsch and Atanasov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.